Physician profile
Ryan M Smith
NPI 1639157365
$124,763.32
in general payments reported to CMS, 2019-2025
25 companies · $7,023 in 2025
The $7,023 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $12K · 2021: $31K · 2022: $11K · 2023: $12K · 2024: $5,351 · 2025: $7,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $5,269 · Travel and Lodging: $383 · Education: $11.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,434.50 |
| Food and Beverage | $5,268.65 |
| Travel and Lodging | $382.62 |
| Education | $11.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69,115.29 | 2019-2025 | Repatha, Repatha, Prolia |
| Esperion Therapeutics, INC. | $27,779.03 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $19,922.55 | 2019-2025 | |
| Boston Scientific Corporation | $2,091.85 | 2019-2025 | Accolade Sr, Resonate El Icd Vr, Watchman Flx |
| Medtronic, INC. | $2,071.25 | 2021-2024 | Micra, Cobalt Dr Mri Surescan |
| Edwards Lifesciences Corporation | $1,051.08 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $619.57 | 2024 | Impella |
| Medtronic Vascular, INC. | $279.04 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $253.22 | 2019-2024 | Lifevest |
| Abbott Laboratories | $250.21 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.53 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $168.95 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $137.22 | 2021-2025 | Eliquis, Camzyos |
| Biotronik INC. | $136.00 | 2020 | |
| Bard Peripheral Vascular, INC. | $135.51 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $123.53 | 2023 | Cios Alpha |
| Pfizer INC. | $118.31 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $100.68 | 2021-2024 | Xarelto |
| Terumo Medical Corporation | $86.48 | 2025 | Angio-Seal |
| Alnylam Pharmaceuticals INC. | $54.62 | 2021-2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $25.24 | 2024 | Evkeeza |
| Amarin Pharma, INC. | $24.71 | 2020 | |
| Sun Pharmaceutical Industries INC. | $16.62 | 2023 | Ilumya |
| Philips North America LLC | $15.76 | 2022 | |
| Irhythm Technologies, INC. | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.